NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

Core Viewpoint - Novo Nordisk A/S has experienced significant stock volatility, with a 200% increase over the past five years but a decline of over 61% in the last year and more than 43% in 2025, raising concerns among investors [1][2] Financial Performance - The company has revised its sales growth expectations to a range of 8% to 14%, with the high end now aligning with the previous low end of 13% to 21% [3] - Operating profit guidance has also been adjusted to a range of 10% to 16%, down from 16% to 24% [3] - Current stock price is $48.86, with a price target of $93.67, indicating a potential upside of 91.71% [11] Leadership Changes - Novo Nordisk appointed Maziar Mike Doustdar as the new CEO, effective August 6, facing challenges from compounded GLP-1 drugs and competition from Eli Lilly [4][5] Market Competition - Compounded GLP-1 drugs are impacting Novo Nordisk's market share, with lower insurance coverage for their obesity drugs compared to diabetes treatments [6][7] - The company has filed nine lawsuits to combat the growth of compounded alternatives, but has not seen significant results [10] Earnings Outlook - Upcoming earnings report on August 6 is critical, especially after a 29% decline in stock value over the last 30 days [11][12] - If results meet or exceed expectations, it may present a buying opportunity as the stock is trading at a discount to historical averages [12][13] Market Dynamics - The market for Ozempic and Wegovy remains large, allowing for competition, but short-term challenges persist [13] - The stock is currently trading below its 50-day simple moving average, indicating potential oversold conditions [13]

Nykredit, one of Denmark’s largest banks, slashed its outlook for the Danish economy after pharmaceutical giant Novo warned of weaker earnings growth and raised fears of a broader slowdown https://t.co/IahazWcogC ...

市场竞争正在趋于白热化。7月31日，礼来公司SURPASS-CVOT 3期临床研究结果公布，旗下"明星减肥 药"替尔泊肽有望从"降糖+减重"双优治疗走向更广阔的前景，为高心血管风险的糖尿病患者带来长期健 康获益。 业内人士认为，玛仕度肽的上市不仅为有减重需求的人群提供了新的选择，也将进一步加速行业内的研 发竞争，推动更多药企加大在减重药物领域的投入，探索更多创新的治疗方案。 业内人士表示，从更广阔的行业角度看，全球肥胖问题给减肥药市场带来了巨大的空间，但企业需面对 更激烈的多靶点药物竞争、更复杂的支付环境以及更严格的监管要求；同时，资本市场对医药企业单一 产品依赖风险的敏感度正在提升。 （文章来源：广州日报） "减重经济"备受关注，减重市场规模逐年上升，然而格局也在不断动态变化中。 近期，国产减肥药玛仕度肽上市，这意味着市场有可能从"双雄争霸"变为"三足鼎立"态势，玛仕度肽将 与减重版司美格鲁肽以及替尔泊肽展开正面竞争。就在日前，诺和诺德公司大幅下调全年财务预期，主 要原因是"Wegovy"（减重版司美格鲁肽制剂）销售失速；与此同时，多家药企仍在加大布局，提速减 重药物研发以抢占更多的市场份额。 作为全球减肥 ...

Investment Rating - The report maintains an investment rating of "Leading the Market" for the chemical pharmaceutical industry, indicating an expected price increase exceeding the benchmark index by over 10% [9]. Core Insights - The GLP-1 and Amylin combination therapy has shown significant potential in weight loss for overweight and obese patients, with clinical trials demonstrating superior results compared to existing treatments [3][4]. - The CagriSema combination of GLP-1 RA and Amylin has achieved major clinical endpoints in Phase III trials, with a weight reduction of -22.7% over 68 weeks, outperforming individual components [4]. - The Amycretin dual agonist has also shown promising results in early clinical trials, with weight reductions of -24.3% and -13.1% in different dosing regimens [5]. Summary by Sections Market Performance - The chemical pharmaceutical industry has experienced rapid growth, particularly in the sales of PDE 3/4 inhibitors for COPD maintenance therapy, with ongoing clinical advancements in related conditions [3]. Drug Evaluation - The report highlights the efficacy and safety of BGB-43395 in breast cancer and solid tumor patients, indicating initial positive outcomes [3]. Clinical Trial Results - In the REDEFINE 1 trial, CagriSema demonstrated a weight loss of -22.7% in non-diabetic obese patients, with 34.7% of participants losing ≥25% of their body weight [4]. - In the REDEFINE 2 trial, diabetic obese patients treated with CagriSema achieved a weight loss of -15.7%, with 22.9% losing ≥20% [4]. Preclinical Findings - The combination of BGM0504 and BGM1812 showed superior weight loss effects in diet-induced obesity models, indicating the potential for further development of GLP-1/GIP RA and Amylin combination therapies [6].

瑞银将诺和诺德评级下调至"中性"，目标价为340丹麦克朗(约合49美元)。 ...

7月底，曾凭司美格鲁肽引领减肥药神话的诺和诺德股价暴跌30%，这也是该百年药企巨头有史以来最大单日跌幅。 前有百年对手礼来的反超，后有美国复方药房的价格战搅局，最早登顶的诺和诺德如今举步维艰，大幅下调全年销售和利润预期，近乎腰斩。 号称千亿美元规模的减肥药市场已然是一片红海，而各大主流减肥药的产品效果都有何区别？从双雄争霸到百花齐放，减肥药市场上新增了哪些玩家？面 临合作翻车、专利即将到期等多重夹击的诺和诺德临场换帅，但资本会认可这位新CEO吗？ 我们深入结合最新的财报数据，一起来看看危机四伏的减肥药混战下半场。 但真正让投资人恐慌的，是诺和诺德这个原本的"赢家"似乎已经没有后招了。 从现在回头看，这次崩盘并非毫无预警。过去一年，诺和诺德已经蒸发了几百亿市值，它押注的第二代新药CagriSema并没有达到市场期待的减重效果； 同时，它也在与礼来的竞争中不断丢分。 2024年，诺和诺德凭借先发者优势，让Wegovy和Ozempic两款药物席卷了全球市场，亲手缔造了减肥药这个市场。 分析师估计，减肥药的年均销售额可能高达1500亿，但现在华尔街开始意识到一个更残酷的现实：减肥药需求的增长，并不代表诺和诺德的产品就 ...

Core Viewpoint - Novo Nordisk (NVO.US) is facing a shareholder lawsuit due to a downward revision of its full-year revenue and operating profit growth expectations, citing challenges in the GLP-1 market as the reason for the adjustment [1] Group 1: Stock Performance - The company's American Depositary Receipts (ADR) experienced a significant drop of over 20% last Tuesday, marking the largest intraday decline since 1987 [1] Group 2: Legal Actions - A group of shareholders filed a proposed class-action lawsuit in federal court in New Jersey on July 28, seeking damages for alleged securities fraud occurring between May 7 and July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the stock price collapse resulting from the lowered performance guidance led to substantial losses for shareholders [1]

Summary of Novo Nordisk Conference Call Company Overview - **Company**: Novo Nordisk (Ticker: NOVOb.CO) - **Industry**: Pharmaceuticals, specifically focusing on diabetes and obesity treatments Key Points and Arguments 1. **Profit Warning**: Novo Nordisk announced reduced expectations for FY25, lowering sales guidance from 13-21% to 8-14% and EBIT from 16-24% to 10-16% due to compounded semaglutide headwinds and slower commercial progress for Ozempic and Wegovy [1][6] 2. **Impact of FX**: The foreign exchange impact on sales and EBIT is expected to be -4% and -7%, respectively, which contributes to the overall downgrade in guidance [1][6] 3. **New CEO Appointment**: Mike Doustdar has been appointed as the new CEO effective August 7th, with a focus on expanding the US market and scaling operations outside the US [1][6] 4. **Market Challenges**: The guidance update is driven by lower growth expectations for Wegovy and Ozempic in the US, competition, and slower-than-expected market expansion [1][6] 5. **Investor Sentiment**: Following the announcement, Novo shares dropped by 24%, indicating investor caution regarding the company's outlook and the obesity market [1][6] 6. **Sales Performance**: In 2Q25, sales growth was reported at 18% at CER, slightly above the Visible Alpha Consensus of 17.1%, while EBIT growth was in line with consensus [6][7] 7. **Future Growth Drivers**: Prior to the profit warning, Novo identified four key areas for potential growth in 2H25, including cessation of compounding and patient switching to branded therapies, but has seen no change in the compounding situation [6][7] 8. **Valuation and Price Target**: A bottom-up DCF analysis suggests a valuation of DKK 720 per share, with a 12-month price target set at DKK 745, reflecting a significant opportunity in diabetes and obesity markets [7][9] 9. **Risks**: Key downside risks include clinical risks related to new drug developments, slower manufacturing scale-up, stronger competition, and sustained price pressure [8][9] Additional Important Information - **Sales and EBIT Estimates**: The implied cuts for FY25 revenue and operating profit are approximately 7% and 10%, respectively, compared to previous estimates [1][5] - **Market Capitalization**: As of the report, Novo Nordisk's market cap is DKK 2.0 trillion ($313.3 billion) [9] - **Long-term Outlook**: The company expects limited changes in the compounding situation until at least the end of 2025, which may necessitate further price cuts to drive access [1][6] This summary encapsulates the critical insights from the conference call, highlighting the challenges and strategic directions for Novo Nordisk in the evolving pharmaceutical landscape.

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **Global Pharmaceuticals** industry, specifically the **Diabetes/Obesity** segment, with an emphasis on the **GLP-1** market [1][2]. Core Insights and Arguments - **Market Dynamics**: The data from IQVIA's dynamic retail data provides insights into market share changes among companies, particularly in the GLP-1 market [2]. - **Novo Nordisk's Earnings**: Novo Nordisk is expected to report its 2Q25 earnings on August 6, 2025, with estimates indicating a **-2%** deviation from Bloomberg consensus, primarily due to lower expectations for **Wegovy** [2]. - **Sales Growth Guidance**: The current sales growth estimate for FY25 is **+15%** at constant exchange rates (CER), which is below the midpoint of the guidance range of **+13-21%**. A further guidance cut is considered unlikely [2]. - **Key Metrics**: - **Ozempic**: Total prescriptions (TRx) increased by approximately **327k** (+4.6% quarter-over-quarter) to **~7.51 million** scripts in 2Q25. However, new to brand prescriptions (NBRx) declined by **-10.6%** [3]. - **Rybelsus**: TRx increased by **~17.8k** (+2.6% q/q) to **~696k** scripts, with NBRx decreasing by **-4.4%** [6]. - **Mounjaro**: TRx grew by **~1.10 million** scripts (+18.2% q/q) to **~7.1 million** scripts, with NBRx growth at **+7.7%** [6]. - **Wegovy**: TRx increased by **~239k** scripts (+9.2% q/q) to **2.83 million** scripts, with NBRx growing by **+14.4%** [6]. - **Zepbound**: TRx grew by **~1.57 million** scripts (+47.3% q/q) to **~4.90 million** scripts, with NBRx increasing by **+35.8%** [6]. Additional Important Insights - **Switching Dynamics**: The report highlights significant switching dynamics among GLP-1 drugs, with **Ozempic**, **Rybelsus**, and **Mounjaro** seeing substantial switches from metformin and other GLP-1 agonists [6][10][11][12]. - **Market Share**: Ozempic's TRx market share within the GLP-1 class is now at **43.4%**, while Mounjaro's share increased to **41.3%** [3][12]. - **Wegovy's Performance**: Despite a growth in TRx, Wegovy's NBRx share is still lower than that of Zepbound, indicating competitive pressures [42][43]. - **Regulatory Approvals**: Zepbound received FDA approval for treating obesity and has shown promising results in various trials, indicating its potential impact on the market [43]. Conclusion - The conference call provides a comprehensive overview of the current state of the GLP-1 market, highlighting the competitive landscape, sales growth expectations, and the dynamics of prescription switching among key products. The insights gathered will be crucial for investors and stakeholders in making informed decisions regarding their positions in the pharmaceutical sector, particularly in diabetes and obesity treatments.